Kazia Therapeutics Limited Adr (KZIA)

Apr 18, 2025

KAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING SCIENTIFIC MEETINGS - marketscreener.com

Apr 18, 2025

Apr 18, 2025

Kazia announces voluntary delisting from ASX - marketscreener.com

Apr 18, 2025

Apr 18, 2025

KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMA - marketscreener.com

Apr 18, 2025

Apr 17, 2025

GBM AGILE OPENS TO PAXALISIB IN EUROPE - MarketScreener

Apr 17, 2025

Apr 17, 2025

KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY - marketscreener.com

Apr 17, 2025

Apr 17, 2025

KAZIA TO PRESENT PAXALISIB DATA IN ADULT AND PEDIATRIC BRAIN CANCER AT SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING - marketscreener.com

Apr 17, 2025

Apr 17, 2025

Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium - marketscreener.com

Apr 17, 2025

Apr 17, 2025

KAZIA THERAPEUTICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES HOSTED BY HC WAINWRIGHT AND LD MICRO - marketscreener.com

Apr 17, 2025

Apr 15, 2025

SEC Form 424B3 filed by Kazia Therapeutics Limited - Quantisnow

Apr 15, 2025

Mar 31, 2025

Kazia Therapeutics sells Cantrixil rights for $1 million - Investing.com India

Mar 31, 2025

Mar 31, 2025

Kazia's Million-Dollar Deal: Cantrixil Cancer Drug IP Rights Sold as Development Path Shifts - Stock Titan

Mar 31, 2025

Mar 13, 2025

Kazia Therapeutics shares annual report details By Investing.com - Investing.com South Africa

Mar 13, 2025

Mar 13, 2025

Kazia Therapeutics shares annual report details - Investing.com

Mar 13, 2025

Mar 12, 2025

Best upcoming stock splits and reverse splits 2024 - Investorsobserver

Mar 12, 2025

Feb 20, 2025

Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's Disease - BioSpace

Feb 20, 2025

Feb 20, 2025

Kazia explores paxalisib for Parkinson's with MJFF grant - Investing.com

Feb 20, 2025

Feb 11, 2025

KZIA’s Stock Journey: What Investors Need to Know About Kazia Therapeutics Limited ADR’s Performance - The InvestChronicle

Feb 11, 2025

Feb 10, 2025

Kazia Therapeutics Limited ADR (KZIA) Stock: Analyzing the Market Value - The News Heater

Feb 10, 2025

Feb 10, 2025

SolarBank Corporation (SUUN) Stock: Evaluating the Market Performance - The News Heater

Feb 10, 2025

Feb 10, 2025

Aditxt Inc (ADTX) Stock: A Look at the Analyst Recommendations - The News Heater

Feb 10, 2025

Feb 08, 2025

Maxim Group Begins Coverage on Kazia Therapeutics (NASDAQ:KZIA) - Defense World

Feb 08, 2025

Jan 30, 2025

10 Best ASX Stocks to Buy According to Hedge Funds - Insider Monkey

Jan 30, 2025

Jan 30, 2025

Game-Changing Cancer Trial: Kazia's New Drug Combo Could Unmask Hidden Breast Cancer Cells - StockTitan

Jan 30, 2025

Jan 27, 2025

Why Kazia Therapeutics (KZIA) Is Among the Best Australian Stocks to Buy Now? - Insider Monkey

Jan 27, 2025

Jan 26, 2025

10 Best Australian Stocks to Buy Now - Insider Monkey

Jan 26, 2025

Jan 14, 2025

Kazia Therapeutics Secures $2M Funding Through Direct Offering to Alumni Capital - StockTitan

Jan 14, 2025

Jan 10, 2025

Kazia Therapeutics secures $2 million in direct offering - Investing.com India

Jan 10, 2025

Jan 10, 2025

Kazia Therapeutics Secures $2M Funding Through Direct Offering at $1.50 Per ADS - StockTitan

Jan 10, 2025

Dec 31, 2024

Why Is Brain Cancer-Focused Kazia Therapeutics Stock Trading Lower On Tuesday? - Yahoo Finance

Dec 31, 2024

Dec 31, 2024

Kazia aligns with FDA on glioblastoma drug study design - Investing.com India

Dec 31, 2024

Dec 31, 2024

Kazia's Brain Cancer Drug Paxalisib Shows 3.8-Month Survival Benefit, FDA Guides Phase 3 Path Forward - StockTitan

Dec 31, 2024

Dec 31, 2024

Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA - marketscreener.com

Dec 31, 2024

Dec 11, 2024

Kazia's Paxalisib Shows Promise in Breast Cancer Trial: Key Data Released at SABCS - StockTitan

Dec 11, 2024

Nov 04, 2024

Kazia sets FDA meeting for glioblastoma drug pathway - Investing.com India

Nov 04, 2024

Nov 04, 2024

Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme - StockTitan

Nov 04, 2024

Oct 30, 2024

U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.65% - MSN

Oct 30, 2024

Oct 29, 2024

Leptomeningeal Metastases Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca - The Globe and Mail

Oct 29, 2024

Oct 29, 2024

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.65% - MSN

Oct 29, 2024

Oct 28, 2024

Upcoming Stock Splits This Week (October 28 to November 1) – Stay Invested - Nasdaq

Oct 28, 2024

Oct 16, 2024

Kazia Therapeutics Adjusts ADS Ratio to Boost Nasdaq Listing - Yahoo Finance

Oct 16, 2024

Oct 11, 2024

B2i Digital Acting as Marketing Partner for Maxim Group's 2024 Healthcare Virtual Summit - Benzinga

Oct 11, 2024

Oct 02, 2024

Paxalisib shows promise in brain metastasis treatment - Investing.com

Oct 02, 2024

Oct 02, 2024

Market Recap: Kazia Therapeutics Limited ADR (KZIA)’s Positive Momentum, Closing at 0.43 - The Dwinnex

Oct 02, 2024

Oct 02, 2024

Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American - StockTitan

Oct 02, 2024

Oct 01, 2024

Kazia Therapeutics Limited ADR (KZIA) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle

Oct 01, 2024